Literature DB >> 1721624

Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis.

A Hamosh1, B C Trapnell, P L Zeitlin, C Montrose-Rafizadeh, B J Rosenstein, R G Crystal, G R Cutting.   

Abstract

Cystic fibrosis (CF) is the most common, lethal inherited disorder in the Caucasian population. We have recently reported two African-American patients with nonsense mutations in each CF gene and severe pancreatic disease, but mild pulmonary disease. In order to examine the effect of these nonsense mutations on CF gene expression, bronchial and nasal epithelial cells were obtained from one of these patients (no. 246), a compound heterozygote for nonsense mutations R553X and W1316X; a healthy normal individual; a patient (no. 528) homozygous for the common CF mutation (delta F508); and a CF patient (no. 272) who carries the R553X mutation and a missense mutation, S549N. When mRNA from bronchial cells of the normal individual, the delta F508 homozygote, and the S549N/R553X compound heterozygote was reverse transcribed and amplified by polymerase chain reaction using primers derived from the CF gene, DNA fragments of the predicted size were observed. However, patient no. 246 with nonsense mutations in each CF gene has no detectable cystic fibrosis transmembrane conductance regulator (CFTR) messenger RNA, and therefore should have severely diminished, and possibly absent, CFTR protein. Furthermore, less than 2% of the CFTR transcripts in nasal epithelial cells from patient no. 272 (S549N/R553X) were derived from the gene with the nonsense mutation. We conclude that severe reduction in CFTR mRNA causes CF, but can have different consequences in the lung and pancreas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721624      PMCID: PMC295756          DOI: 10.1172/JCI115510

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  Differences in expression of cystic fibrosis in blacks and whites.

Authors:  S A McColley; B J Rosenstein; G R Cutting
Journal:  Am J Dis Child       Date:  1991-01

3.  The chest roentgenogram in cystic fibrosis: a new scoring system.

Authors:  D Brasfield; G Hicks; S Soong; R E Tiller
Journal:  Pediatrics       Date:  1979-01       Impact factor: 7.124

4.  Translation to near the distal end of the penultimate exon is required for normal levels of spliced triosephosphate isomerase mRNA.

Authors:  J Cheng; M Fogel-Petrovic; L E Maquat
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

Review 5.  The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells.

Authors:  R Moll; W W Franke; D L Schiller; B Geiger; R Krepler
Journal:  Cell       Date:  1982-11       Impact factor: 41.582

6.  A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein.

Authors:  G R Cutting; L M Kasch; B J Rosenstein; J Zielenski; L C Tsui; S E Antonarakis; H H Kazazian
Journal:  Nature       Date:  1990-07-26       Impact factor: 49.962

7.  Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis.

Authors:  B C Trapnell; C S Chu; P K Paakko; T C Banks; K Yoshimura; V J Ferrans; M S Chernick; R G Crystal
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

8.  Defective acidification of intracellular organelles in cystic fibrosis.

Authors:  J Barasch; B Kiss; A Prince; L Saiman; D Gruenert; Q al-Awqati
Journal:  Nature       Date:  1991-07-04       Impact factor: 49.962

9.  Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance.

Authors:  N Kartner; J W Hanrahan; T J Jensen; A L Naismith; S Z Sun; C A Ackerley; E F Reyes; L C Tsui; J M Rommens; C E Bear
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

10.  Nonsense mutation in the glycoprotein Ib alpha coding sequence associated with Bernard-Soulier syndrome.

Authors:  J Ware; S R Russell; V Vicente; R E Scharf; A Tomer; R McMillan; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  43 in total

Review 1.  Novel pharmacologic therapies for cystic fibrosis.

Authors:  P L Zeitlin
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

2.  CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR.

Authors:  Molly B Sheridan; Timothy W Hefferon; Nulang Wang; Christian Merlo; Carlos Milla; Drucy Borowitz; Eric D Green; Peter J Mogayzel; Garry R Cutting
Journal:  J Med Genet       Date:  2010-11-20       Impact factor: 6.318

3.  Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X.

Authors:  Isabel Aznarez; Julian Zielenski; Johanna M Rommens; Benjamin J Blencowe; Lap-Chee Tsui
Journal:  J Med Genet       Date:  2007-05       Impact factor: 6.318

4.  CFTR mutations in Chilean cystic fibrosis patients.

Authors:  J Rios; O Orellana; M Aspillaga; I Avendano; I Largo; N Riveros
Journal:  Hum Genet       Date:  1994-09       Impact factor: 4.132

5.  Nonsense mutation in the phosphofructokinase muscle subunit gene associated with retention of intron 10 in one of the isolated transcripts in Ashkenazi Jewish patients with Tarui disease.

Authors:  O Vasconcelos; K Sivakumar; M C Dalakas; M Quezado; J Nagle; M Leon-Monzon; M Dubnick; D C Gajdusek; L G Goldfarb
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 6.  Spectrum of mutations in cystic fibrosis.

Authors:  G R Cutting
Journal:  J Bioenerg Biomembr       Date:  1993-02       Impact factor: 2.945

7.  Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII--and their population frequency.

Authors:  J B Sherman; N Raben; C Nicastri; Z Argov; H Nakajima; E M Adams; C M Eng; T M Cowan; P H Plotz
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

8.  Recurrent nonsense mutations within the type VII collagen gene in patients with severe recessive dystrophic epidermolysis bullosa.

Authors:  A Hovnanian; L Hilal; C Blanchet-Bardon; Y de Prost; A M Christiano; J Uitto; M Goossens
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

9.  Spectrum of small mutations in the dystrophin coding region.

Authors:  T W Prior; C Bartolo; D K Pearl; A C Papp; P J Snyder; M S Sedra; A H Burghes; J R Mendell
Journal:  Am J Hum Genet       Date:  1995-07       Impact factor: 11.025

10.  Defective splicing of mRNA from one COL1A1 allele of type I collagen in nondeforming (type I) osteogenesis imperfecta.

Authors:  M L Stover; D Primorac; S C Liu; M B McKinstry; D W Rowe
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.